---
schema_version: "secwatch.filing_event.v1"
accession: "0001534120-26-000042"
form_type: "8-K"
ticker: "AVTX"
cik: "0001534120"
company_name: "Avalo Therapeutics, Inc."
filed_at: "2026-06-16T11:18:22+00:00"
generated_at: "2026-06-16T11:20:09.007524+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Avalo Therapeutics expands pipeline with AVTX-010, a long-acting anti-IL-1β mAb; IND planned H1 2027

## Summary
- AVTX-010 is an engineered anti-IL-1β mAb for hidradenitis suppurativa and other inflammatory disorders.
- IND submission for AVTX-010 expected in the first half of 2027.
- Building on abdakibart Phase 2 LOTUS data and the IL-1β pathway conviction.
- CEO cites less frequent dosing as key driver for physician and patient preference.
- Follows transformational financing completed in May 2026.

## SEC filing metadata
- accession: 0001534120-26-000042
- form_type: 8-K
- ticker: AVTX
- cik: 0001534120
- company_name: Avalo Therapeutics, Inc.
- filed_at: 2026-06-16T11:18:22+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534120/000153412026000042/0001534120-26-000042-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534120/000153412026000042/avtx-20260616.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001534120-26-000042
- JSON: https://secwatch.observer/filing/0001534120-26-000042.json
- Plain text: https://secwatch.observer/filing/0001534120-26-000042.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.